[1]
L. Martin, S. Alibhai, M. Komisarenko, N. Timilshina, and A. Finelli, “Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302”, CUAJ, vol. 13, no. 6, Nov. 2018.